Constance M. Yuan

National Institutes of Health — United States

Medicine · Health Sciences

47h-index14.6kcitations258works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Chronic Lymphocytic Leukemia Research(83), Lymphoma Diagnosis and Treatment(73), CAR-T cell therapy research(69), Multiple Myeloma Research and Treatments(56), Immunodeficiency and Autoimmune Disorders(31)

Publications258 total

CRLF2-rearrangement and Extramedullary Disease in B-cell Acute Lymphoblastic Leukemia: A Possible Link?
Blood Advances·2026Open Access
Ten-year experience of CD22 CAR T cells for children and young adults with B-cell acute lymphoblastic leukemia
Blood Advances·2025Open Access
A Decade of Ibrutinib for CLL with and without TP53 Aberration: Final Report on an Investigator-Sponsored Phase 2 Study
Blood·2025
Affinity-matured CD72-targeting nanobody CAR T cells enhance elimination of antigen-low B-cell malignancies
Journal for ImmunoTherapy of Cancer·2025Open Access
Phase 2 trial of cladribine plus immediate rituximab for 1st-line treatment of hairy cell leukemia – long term follow-up of original and additional patient cohorts
Blood·2025Open Access
MAP2K1 and MAP2K2 genes alterations in hairy cell leukemia and hairy cell leukemia variant.
Blood·2025Open Access
CD19/22 CAR T-cells in children and young adults with B-ALL: Final Phase 1 trial results
Blood·2025
Phase 2 trial of encorafenib plus binimetinib for patients with BRAF V600 mutated relapsed/refractory hairy cell leukemia
Blood·2025Open Access
Harmonization on defining B‐cell recovery post CD19‐CAR T‐cell therapy in B‐cell acute lymphoblastic leukemia: An international consensus statement
HemaSphere·2025Open Access
Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia
Blood·2025· 1 citedOpen Access
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies
Cytotherapy·2025Open Access
Primary Results from a Phase 2 Response-Adapted Study of Daratumumab, Carfilzomib, and Dexamethasone (DKd) in Patients with High-Risk Smoldering Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
Molecular analysis of bilateral T-cell vitreoretinal lymphoma
npj Precision Oncology·2025Open Access
Complete Response in Hairy Cell Leukemia to Anti-CD22 CAR T-Cell Therapy
JCO Precision Oncology·2025Open Access
Affinity-matured CD72-targeting Nanobody CAR T-cells Enhance Elimination of Antigen-Low B-cell Malignancies
2025· 1 citedOpen Access
Abstract 4820: Anti-CD72 nanobody-based CAR-T affinity maturation leads to improved in vitro efficacy versus low antigen density lymphoma models, but limited benefit in vivo
Cancer Research·2025
Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia
Blood·2025· 16 citedOpen Access
Prospective Study Utilizing PET-CT and Next-Generation Sequencing to Evaluate for Peri-CAR T-Cell Non-CNS Extramedullary Disease in B-Acute Lymphoblastic Leukemia
Transplantation and Cellular Therapy·2025
Potentiating CD20 monoclonal antibody therapy by targeting complement C3 fragments covalently deposited on lymphoma cells
Blood·2025· 2 citedOpen Access
Non-V600E <i>BRAF</i> mutations and treatment for hairy cell leukemia
Blood·2024· 7 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Maryalice Stetler‐Stevenson(43), Nirali N. Shah(21), Terry J. Fry(16), Irina Marić(16), Bonnie Yates(15), Haneen Shalabi(12), Cindy Delbrook(10), Katherine R. Calvo(10), Seth M. Steinberg(9), Adrian Wiestner(9), Daniel W. Lee(9), Hao‐Wei Wang(9), James N. Kochenderfer(8), Crystal L. Mackall(8), Gerald E. Marti(8), David F. Stroncek(7), Mohammed Farooqui(7), Sarah E. M. Herman(7), Haiying Qin(6), Stefania Pittaluga(6)